Stephen Wiviott, MD
Cardiovascular Disease · Boston, MANPI 1932126471
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $37,794 of the $48,546 with a category attached, or 77.9%. Merck accounts for 80.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $22,931 and has fallen 91.7% since, to $1,899 in 2025. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $851.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$39K
- Siemens Medical Solutions USA, Inc.$9K
- Astrazeneca UK Limited$187
- Esperion Therapeutics, Inc.$131
- Amgen$56
Across 162 payments — averaging $181,259 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$20M
- Astrazeneca UK Limited$9.2M
- Novo Nordisk AS$203K
- Amgen$7K
What the payments were for
- Consulting fees$9,00019%
- Travel & lodging$37,79478%
- Food & beverage$1,7524%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 49 | $39,173 |
| Siemens Medical Solutions USA, Inc. | 4 | $9,000 |
| Astrazeneca UK Limited | 2 | $187 |
| Esperion Therapeutics, Inc. | 1 | $131 |
| Amgen | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,546 in reported general payments places this provider in the 90th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $27,884 |
| JardianceEmpagliflozin | 15 | $25,867 |
| Ezetimibe | 18 | $1,466 |
| Metoprolol Succinate | 27 | $478 |
| Atorvastatin Calcium | 24 | $340 |
| Chlorthalidone | 18 | $302 |
| ClopidogrelClopidogrel Bisulfate | 15 | $298 |
| Rosuvastatin Calcium | 24 | $250 |
| FenofibrateFenofibrate,micronized | 11 | $217 |
| Losartan Potassium | 23 | $184 |
| Amlodipine Besylate | 11 | $86 |
| Hydrochlorothiazide | 13 | $74 |
| Furosemide | 13 | $65 |
| Carvedilol | 15 | $64 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.